Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis.

ABSTRACT:

Purpose

To assess and compare the relative efficacy and safety of anti-SARS-CoV-2 antibody regimens for COVID-19.

Methods

This systematic review and random-effects network meta-analysis was conducted according to PRISMA-NMA. Literature searches were conducted across MEDLINE, EMBASE, PubMed, Web of Science, CENTRAL, and CNKI up to February 20th, 2022. Interventions were ranked using P scores.

Results

Fifty-five RCTs (N = 45,005) were included in the review. Bamlanivimab + etesevimab (OR 0.13, 95% CI 0.02-0.77) was associated with a significant reduction in mortality compared to standard of care/placebo. Casirivimab + imdevimab reduced mortality (OR 0.67, 95% CI 0.50-0.91) in baseline seronegative patients only. Four different regimens led to a significant decrease in t

SUBMITTER: Deng J 

PROVIDER: S-EPMC9016212 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature